Categories: The Charlton Centre

What is a biosimilar?

In a previous blog we spoke about what a biologic medication is, and how it is produced through the programming of live cells to produce a treatment that mimics a protein structure in a human. Biosimilars are produced after the originator biologic’s patent has expired. The living cells used to produce the biosimilar will be different than the originator biologic and therefore the final product can never be called identical, but can be considered highly similar.

Health Canada requires testing in humans to ensure the biosimilar will be as effective and safe as the original biologic. We now have two biosimilars for the medication Remicade (infliximab): Inflectra and Renflexis.. There are also two biosimilars for the medication Enbrel (etanercept):Brenzys and Erelzi. There are many more on the horizon.

The cost of biosimilars is significantly less than the originator biologic and therefore many government and private insurance plans are requesting a biosimilar be used when a person is first starting this type of treatment. Many Canadians are currently using biosimilars with great success.

As a cost saving measure, there are now insurance plans requesting patients who are on a biologic and doing well, switch to the biosimilar (if one exists for the biologic they are taking). There are many studies that have been done assessing switching from the originator biologic to a biosimilar. In most trials, patients experienced no changes. There are however situations where the switch resulted in greater improvement in a person’s disease and others where the person’s condition worsened. As we gain more experience with biosimilars, it will be important to track each manufacturer’s biosimilar to monitor any changes in effectiveness and adverse effects. There are no studies regarding switching between different biosimilars.


Carolyn Whiskin is the Pharmacy Manager for Charlton Health.  Carolyn specializes in the treatment of autoimmune diseases, pharmaceutical compounding, women’s health, pain and smoking cessation. Carolyn has won provincial and national awards for her commitment to patient care and public service.

admin

Share
Published by
admin

Recent Posts

Happy Back-to-School!

This week, many will return to school, and it's no secret that the back-to-school season…

2 weeks ago

Staying Hydrated in the Summer

Staying well hydrated is important in every season, but it becomes especially crucial during thesummer.…

3 weeks ago

World Hepatitis Day

Last week, on July 28th, we observed World Hepatitis Day, a day dedicated to raising…

1 month ago

Traveling This Summer with Biologics? Here’s What You Need to Know

Summer is a great time to get out and see new sights. Whether you're planning…

2 months ago

Summer Sun Safety

Now that the warmer weather is here, many of us are spending more time enjoying…

2 months ago

New Biosimilars of Xolair and Actemra Now Available: Omlyclo and Tyenne

Biosimilars are becoming more common in Canada, offering patients trusted alternatives to the originator biologic medication. Biosimilars…

3 months ago